Edgar Filing: ENZO BIOCHEM INC - Form 8-K

Form 8-K September 20, 2016
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 20, 2016
Enzo Biochem, Inc.
(Exact Name of Registrant as Specified in Its Charter)
New York
(State or Other Jurisdiction of Incorporation)
001-09974 13-2866202 (Commission File Number) (IRS Employer Identification No.)

10022

ENZO BIOCHEM INC

527 Madison Avenue New York, New York

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

(Address of Principal Executive Offices) (Zip Code)

(212) 583-0100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ENZO BIOCHEM INC - Form 8-K

Item 8.01 Other events

On September 20, 2016, Enzo Biochem, Inc. (the "Company") issued a press release titled "Enzo Biochem Announces New York State Health Department Approval of New Easily Adaptable, Cost Effective Cardiac Assay"

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of Enzo Biochem, Inc., dated September 20, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: September 20, 2016 By:/s/ Barry W. Weiner Barry W. Weiner

President